Multicenter cooperative observational study of reactivation of hepatitis B virus caused by everolimus or sorafenib
Not Applicable
- Conditions
- Maligant tumor patients with high risk of hepatitis B viral reactivation receiving chemotherapy in which everolimus or sorafenib is contained.
- Registration Number
- JPRN-UMIN000005370
- Lead Sponsor
- Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) No prior treatment of everolimus and sorafenib 2) During hemodialyis or planning to introuce hemodialyis. 3) Seropositivity to HCVAb 4) Seropositivity for HBsAb only with a history of HBV vaccination 5) Not eligible judged by investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method